Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Anastasios Stathis(Princess Margaret Cancer Centre), C. Sessa(Hospital Clínico Universitario de Valencia), Sara Allegrini(Institute of Oncology Research), Markus Joerger(Kantonsspital St. Gallen), Roger von Moos(Kantonsspital Graubünden), Christoph Ackermann(University of St.Gallen), Dagmar Hess(University of St.Gallen), Piera Gargiulo(Swiss Group For Clinical Cancer Research), Simona Berardi(Swiss Group For Clinical Cancer Research), Krisztián Homicskó(University Hospital of Lausanne), Michael Mark(Kantonsspital Graubünden), Gaia Griguolo(University of North Carolina at Chapel Hill), Carlo V. Catapano(Institute of Oncology Research), Alexandros Xyrafas(Swiss Group For Clinical Cancer Research), Milica Enoiu(Swiss Group For Clinical Cancer Research)
Cited by 32
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|580
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
|Clinical Cancer Research|2014|326
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|288